The revolution of the precision medicine shattered the medical world order. As other companies scrambled to adjust, OncoDxRx took a different path. While many companies cozied up to precision diagnostics or therapeutics superpowers, OncoDxRx charted a course of self-reliance. This bold gamble is now paying dividends.

A recent essay shared OncoDxRx’s rise as a precision diagnostics powerhouse, even eclipsing some major players in certain areas, which is a story of remarkable foresight and unwavering independence.

OncoDxRx has exhibited an independent streak within the industry, most notably focusing solely on one-of-a-kind, exclusive liquid biopsy technologies. This independence extended to its pipelines, where the company developed a robust drug response prediction assay called PGA (Patient-derived Gene expression-informed Anticancer drug efficacy), reducing clinicians’ reliance on biomarker testing that only qualifies 20-30% of cancer patients for precision therapy.

This has helped OncoDxRx gain technical barrier and market shares while other companies have struggled competitions commercially.

A critical aspect of OncoDxRx’s technological exclusiveness is its approaches to innovation. Unlike many companies, OncoDxRx insists on developing its unique technologies intellectually and internally. The independence in core technology development stands in contrast to many companies, which often incorporate universally-available systems and employ similar protocols.

The turning point for OncoDxRx came gradually but decisively. OncoDxRx’s success can be attributed to several factors. The PGA, a gene-to-drug prediction assay, offers a balanced mix of capabilities to fulfill the gaps in biomarker testing, benefiting many more patients.

Additionally, OncoDxRx’s ability to expedite implementation by utilizing qPCR platform to minimize cost, time and training has been a major advantage.

Unlike the other diagnostic companies, which are protective of their NGS instrumentation, reagents and bioinformatics and imposes stringent conditions on their partners, OncoDxRx’s approach provides more flexibility to laboratories seeking to access exclusive technology and at the same time, maintain a labor- and cost-efficient workflow.